Barclays notes that SpringWorks Therapeutics’ (SWTX) Ogsiveo was included on today’s Committee for Medicinal Products for Human Use agenda, which could lead to a positive opinion for Ogsiveo and enable EU approval. Such an event “could be an important de-risker for potential acquisition of the company” by Merck KGaA (MKGAY), argues the analyst, who has an Overweight rating and $63 price target on SpringWorks shares.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SWTX: